Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01644149 · ClinicalTrials.gov registry record · Phase 4
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
A Phase 4 study of Influenza Prophylaxis, sponsored by PharmaJet.
- Completed
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT01644149 is a Phase 4 study of Influenza Prophylaxis that has completed, run by PharmaJet. The registered enrollment target is 83 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01644149, a Phase 4 study of Influenza Prophylaxis, has completed, sponsored by PharmaJet.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response. A secondary objective was to compare the safety of the two delivery methods.
Conditions Studied
Interventions
- DEVICE Stratis Jet Injector
- DEVICE Needle and Syringe
- BIOLOGICAL 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study Locations (1)
Colorado
- Bel-Rea Institute - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01644149
The ClinicalTrials.gov registry entry for NCT01644149 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaJet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza Prophylaxis appearing as the primary indexed condition, and to 3 interventions - of which Stratis Jet Injector is the first listed.
NCT01644149 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01644149 about?
NCT01644149 is a clinical study titled "Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe". The primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response. A secondary objective was to compare the safety of the two delivery methods.
What is the current status of trial NCT01644149?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2012-01. Estimated completion is 2012-02.
What conditions does trial NCT01644149 study?
This clinical trial studies the following conditions: Influenza Prophylaxis.
What interventions are being tested in trial NCT01644149?
The interventions under investigation include: Stratis Jet Injector (DEVICE), Needle and Syringe (DEVICE), 2011-2012 Fluzone trivalent inactivated influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01644149?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01644149 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.